全文获取类型
收费全文 | 4866篇 |
免费 | 258篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 344篇 |
妇产科学 | 73篇 |
基础医学 | 480篇 |
口腔科学 | 141篇 |
临床医学 | 372篇 |
内科学 | 1189篇 |
皮肤病学 | 83篇 |
神经病学 | 225篇 |
特种医学 | 114篇 |
外科学 | 546篇 |
综合类 | 174篇 |
预防医学 | 292篇 |
眼科学 | 142篇 |
药学 | 540篇 |
中国医学 | 51篇 |
肿瘤学 | 307篇 |
出版年
2023年 | 54篇 |
2022年 | 134篇 |
2021年 | 188篇 |
2020年 | 96篇 |
2019年 | 121篇 |
2018年 | 216篇 |
2017年 | 139篇 |
2016年 | 186篇 |
2015年 | 179篇 |
2014年 | 239篇 |
2013年 | 273篇 |
2012年 | 418篇 |
2011年 | 436篇 |
2010年 | 255篇 |
2009年 | 168篇 |
2008年 | 224篇 |
2007年 | 217篇 |
2006年 | 209篇 |
2005年 | 175篇 |
2004年 | 160篇 |
2003年 | 185篇 |
2002年 | 149篇 |
2001年 | 65篇 |
2000年 | 55篇 |
1999年 | 37篇 |
1998年 | 38篇 |
1997年 | 27篇 |
1996年 | 21篇 |
1995年 | 18篇 |
1994年 | 18篇 |
1993年 | 13篇 |
1992年 | 23篇 |
1991年 | 37篇 |
1990年 | 35篇 |
1989年 | 31篇 |
1988年 | 41篇 |
1987年 | 25篇 |
1986年 | 23篇 |
1985年 | 30篇 |
1984年 | 13篇 |
1983年 | 11篇 |
1982年 | 14篇 |
1981年 | 15篇 |
1979年 | 23篇 |
1978年 | 23篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1974年 | 7篇 |
1972年 | 8篇 |
1969年 | 13篇 |
排序方式: 共有5139条查询结果,搜索用时 15 毫秒
1.
Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted important steps where we need to take precautions before starting tofacitinib. 相似文献
2.
3.
Uday Yanamandra Prateek Deo Kamal Kant Sahu Ram Vasudevan Nampoothiri Nalini Gupta Anusree Prabhakaran Deb Prasad Dhibhar Alka Khadwal Gaurav Prakash Man Upadesh Singh Sachdeva Deepesh Lad Neelam Varma Subhash Varma Pankaj Malhotra 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):183-189.e1
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献4.
5.
6.
Xiaoguang Chen Yi Li Lei Wang Mark Katakowski Lijie Zhang Jieli Chen Yongxian Xu Subhash C. Gautam Michael Chopp 《Neuropathology》2002,22(4):275-279
Intravenous administration of human bone marrow stromal cells (hMSCs) after middle cerebral artery occlusion (MCAo) in rats provides functional benefit. We tested the hypothesis that these functional benefits are derived in part from hMSC production of growth and trophic factors. Quantitative sandwich enzyme‐linked immunosorbent assay (ELISA) of hMSCs cultured with normal and MCAo brain extracts were performed. hMSCs cultured in supernatant derived from ischemic brain extracts increased production of brain‐derived neurotrophic factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). These neurotrophins and angiogenic growth factors increased in a post‐ischemia time‐dependent manner. The hMSC capacity to increase expression of growth and trophic factors may be the key to the benefit provided by transplanted hMSCs in the ischemic brain. 相似文献
7.
8.
9.
The optimal conditions for inactivation of Bordetella pertussis organisms with glutaraldehyde for the production of a safe and potent whole cell pertussis vaccine were investigated. Two bacterial harvests from B. pertussis strain 10536 were treated with glutaraldehyde, each with 0.025, 0.05 and 0.1% concentrations of glutaraldehyde for 10, 60 and 120 min. The nine types of glutaraldehyde-inactivated pertussis vaccine (GIPV) and conventional heat-inactivated pertussis vaccine (HIPV) preparations made from two bacterial harvests were comparatively evaluated for the mouse weight gain test (MWGT), potency, and the histamine-sensitization (HS) and leucocytosis-promoting-factor (LPF) tests. The minimum period for killing the B. pertussis organisms with glutaraldehyde was>10 min for 0.025%, 10 min for 0.05% and 5 min for 0.1% concentration. The average loss in opacity varied from 5 to 10% for GIPV preparations and was 14% for HIPV preparations. The GIPV preparations except those inactivated with 0.025% glutaraldehyde for 10 min (GIPV-A) were much less toxic than the HIPV preparations in the MWGT. The GIPV-A preparations did not pass the MWGT. The GIPV preparations were also much less toxic in HS and LPF tests than the HIPV preparation. The potency of GIPV preparations inactivated with 0.05% glutaraldehyde for 10 min (GIPV-D) was similar to that of HIPV preparations. The prolonged treatments with glutaraldehyde reduced the potency. The GIPV-D preparation with good potency and less toxicity was found to be inactivated with glutaraldehyde under optimal conditions. All the preparations were innocuous in the abnormal toxicity test. 相似文献
10.